AU2010275678B2 - Method for obtaining myofibroblasts - Google Patents
Method for obtaining myofibroblasts Download PDFInfo
- Publication number
- AU2010275678B2 AU2010275678B2 AU2010275678A AU2010275678A AU2010275678B2 AU 2010275678 B2 AU2010275678 B2 AU 2010275678B2 AU 2010275678 A AU2010275678 A AU 2010275678A AU 2010275678 A AU2010275678 A AU 2010275678A AU 2010275678 B2 AU2010275678 B2 AU 2010275678B2
- Authority
- AU
- Australia
- Prior art keywords
- cells
- myofibroblasts
- serum
- medium
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 210000000651 myofibroblast Anatomy 0.000 title claims abstract description 61
- 238000000034 method Methods 0.000 title claims abstract description 32
- 210000004027 cell Anatomy 0.000 claims abstract description 74
- 210000002950 fibroblast Anatomy 0.000 claims abstract description 35
- 239000002609 medium Substances 0.000 claims description 29
- 239000001963 growth medium Substances 0.000 claims description 26
- 210000002966 serum Anatomy 0.000 claims description 24
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- 230000008569 process Effects 0.000 claims description 23
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 claims description 16
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 16
- 238000012258 culturing Methods 0.000 claims description 15
- 238000000746 purification Methods 0.000 claims description 14
- 238000004113 cell culture Methods 0.000 claims description 11
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 239000003242 anti bacterial agent Substances 0.000 claims description 9
- 102000004877 Insulin Human genes 0.000 claims description 8
- 108090001061 Insulin Proteins 0.000 claims description 8
- 239000006285 cell suspension Substances 0.000 claims description 8
- 229960000890 hydrocortisone Drugs 0.000 claims description 8
- 229940125396 insulin Drugs 0.000 claims description 8
- 241000283690 Bos taurus Species 0.000 claims description 7
- 201000009030 Carcinoma Diseases 0.000 claims description 7
- 230000001817 pituitary effect Effects 0.000 claims description 7
- ZWQVYZXPYSYPJD-RYUDHWBXSA-N Glu-Gly-Phe Chemical compound OC(=O)CC[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CC1=CC=CC=C1 ZWQVYZXPYSYPJD-RYUDHWBXSA-N 0.000 claims description 6
- 230000012010 growth Effects 0.000 claims description 6
- 239000012679 serum free medium Substances 0.000 claims description 5
- 239000004017 serum-free culture medium Substances 0.000 abstract description 9
- 150000001875 compounds Chemical class 0.000 abstract description 4
- 239000000090 biomarker Substances 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 238000010200 validation analysis Methods 0.000 abstract description 2
- 230000000118 anti-neoplastic effect Effects 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 description 14
- 239000000523 sample Substances 0.000 description 13
- 239000000203 mixture Substances 0.000 description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 9
- 239000007640 basal medium Substances 0.000 description 9
- 230000006862 enzymatic digestion Effects 0.000 description 9
- 210000002919 epithelial cell Anatomy 0.000 description 9
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 8
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 8
- 239000012472 biological sample Substances 0.000 description 8
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 7
- 239000003550 marker Substances 0.000 description 7
- 239000013589 supplement Substances 0.000 description 5
- 102000007469 Actins Human genes 0.000 description 4
- 108010085238 Actins Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 210000002460 smooth muscle Anatomy 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000008188 pellet Substances 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229930182566 Gentamicin Natural products 0.000 description 2
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 2
- 206010052428 Wound Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
- 229960003942 amphotericin b Drugs 0.000 description 2
- 210000004102 animal cell Anatomy 0.000 description 2
- 230000031018 biological processes and functions Effects 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 230000007882 cirrhosis Effects 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 229960002518 gentamicin Drugs 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 230000002055 immunohistochemical effect Effects 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000003169 placental effect Effects 0.000 description 2
- 230000001023 pro-angiogenic effect Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 230000009758 senescence Effects 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 230000017423 tissue regeneration Effects 0.000 description 2
- 230000007838 tissue remodeling Effects 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 102000029816 Collagenase Human genes 0.000 description 1
- 108060005980 Collagenase Proteins 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 101800003838 Epidermal growth factor Proteins 0.000 description 1
- 108010003272 Hyaluronate lyase Proteins 0.000 description 1
- 102000001974 Hyaluronidases Human genes 0.000 description 1
- 231100000750 In vitro toxicology Toxicity 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- SUHOOTKUPISOBE-UHFFFAOYSA-N O-phosphoethanolamine Chemical compound NCCOP(O)(O)=O SUHOOTKUPISOBE-UHFFFAOYSA-N 0.000 description 1
- 208000037273 Pathologic Processes Diseases 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 102000004338 Transferrin Human genes 0.000 description 1
- 108090000901 Transferrin Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 229960000723 ampicillin Drugs 0.000 description 1
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229960002424 collagenase Drugs 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 229940116977 epidermal growth factor Drugs 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229960002773 hyaluronidase Drugs 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- -1 normocin (Invivogen) Chemical compound 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 230000009054 pathological process Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 231100000241 scar Toxicity 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000002536 stromal cell Anatomy 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 239000012581 transferrin Substances 0.000 description 1
- 239000006163 transport media Substances 0.000 description 1
- 230000001173 tumoral effect Effects 0.000 description 1
- WBPYTXDJUQJLPQ-VMXQISHHSA-N tylosin Chemical compound O([C@@H]1[C@@H](C)O[C@H]([C@@H]([C@H]1N(C)C)O)O[C@@H]1[C@@H](C)[C@H](O)CC(=O)O[C@@H]([C@H](/C=C(\C)/C=C/C(=O)[C@H](C)C[C@@H]1CC=O)CO[C@H]1[C@@H]([C@H](OC)[C@H](O)[C@@H](C)O1)OC)CC)[C@H]1C[C@@](C)(O)[C@@H](O)[C@H](C)O1 WBPYTXDJUQJLPQ-VMXQISHHSA-N 0.000 description 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000011179 visual inspection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
- C12N5/0656—Adult fibroblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/05—Inorganic components
- C12N2500/10—Metals; Metal chelators
- C12N2500/20—Transition metals
- C12N2500/24—Iron; Fe chelators; Transferrin
- C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/90—Serum-free medium, which may still contain naturally-sourced components
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/10—Growth factors
- C12N2501/11—Epidermal growth factor [EGF]
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Rheumatology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0955216 | 2009-07-24 | ||
| FR0955216A FR2948381B1 (fr) | 2009-07-24 | 2009-07-24 | Procede d'obtention de myofibroblastes. |
| PCT/EP2010/059478 WO2011009706A1 (fr) | 2009-07-24 | 2010-07-02 | Procede d'obtention de myofibroblastes |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2010275678A1 AU2010275678A1 (en) | 2012-02-09 |
| AU2010275678B2 true AU2010275678B2 (en) | 2016-06-16 |
Family
ID=41460947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2010275678A Ceased AU2010275678B2 (en) | 2009-07-24 | 2010-07-02 | Method for obtaining myofibroblasts |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9243228B2 (https=) |
| EP (1) | EP2456854B1 (https=) |
| JP (1) | JP5758891B2 (https=) |
| CN (1) | CN102471761A (https=) |
| AU (1) | AU2010275678B2 (https=) |
| CA (1) | CA2767929A1 (https=) |
| ES (1) | ES2650664T3 (https=) |
| FR (1) | FR2948381B1 (https=) |
| IL (1) | IL217352A (https=) |
| MX (1) | MX2012001004A (https=) |
| NZ (1) | NZ597728A (https=) |
| WO (1) | WO2011009706A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104096265B (zh) * | 2014-07-01 | 2016-03-23 | 温州医科大学 | 一种用于构建人工血管模型的三维收缩模型的制备方法 |
| CN104630134A (zh) * | 2015-02-15 | 2015-05-20 | 叶中华 | 阴道上皮细胞培养基及阴道上皮细胞培养方法 |
| CN111500527A (zh) * | 2020-06-30 | 2020-08-07 | 北京昱龙盛世生物科技有限公司 | 一种表皮干细胞的分离培养方法 |
| EP4398948A4 (en) * | 2021-09-07 | 2025-07-09 | Wisconsin Alumni Res Found | CARDIAC FIBROBLAST-DERIVED EXTRACELLULAR MATRIX |
| CN115197892A (zh) * | 2022-06-13 | 2022-10-18 | 浙江省人民医院 | 一种人甲状腺乳头状癌组织中成纤维细胞的分离培养方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5573937A (en) * | 1989-12-07 | 1996-11-12 | Snow Brand Milk Products Co., Ltd. | Serum free culture medium |
| KR20060114381A (ko) * | 2004-02-13 | 2006-11-06 | 레프로셀 인코퍼레이티드 | 배아줄기세포용 피더세포 작성 배지 및 피더세포 |
| ATE541919T1 (de) * | 2005-02-11 | 2012-02-15 | Novo Nordisk Healthcare Ag | Herstellung eines proteins in serumfreier zellkultur, die ein proteinhydrolysat aus pflanzen enthält |
-
2009
- 2009-07-24 FR FR0955216A patent/FR2948381B1/fr active Active
-
2010
- 2010-07-02 AU AU2010275678A patent/AU2010275678B2/en not_active Ceased
- 2010-07-02 CN CN2010800324369A patent/CN102471761A/zh active Pending
- 2010-07-02 EP EP10726999.5A patent/EP2456854B1/fr not_active Not-in-force
- 2010-07-02 JP JP2012520985A patent/JP5758891B2/ja not_active Expired - Fee Related
- 2010-07-02 US US13/386,522 patent/US9243228B2/en not_active Expired - Fee Related
- 2010-07-02 ES ES10726999.5T patent/ES2650664T3/es active Active
- 2010-07-02 CA CA2767929A patent/CA2767929A1/fr not_active Abandoned
- 2010-07-02 WO PCT/EP2010/059478 patent/WO2011009706A1/fr not_active Ceased
- 2010-07-02 MX MX2012001004A patent/MX2012001004A/es active IP Right Grant
- 2010-07-02 NZ NZ597728A patent/NZ597728A/xx not_active IP Right Cessation
-
2012
- 2012-01-03 IL IL217352A patent/IL217352A/en not_active IP Right Cessation
Non-Patent Citations (2)
| Title |
|---|
| Jester et al (1996) Cornea, vol. 15, pps 505-516 * |
| Webber et al (1999) Carcinogenesis, vol. 20, pps 1185-1192 * |
Also Published As
| Publication number | Publication date |
|---|---|
| US20120190109A1 (en) | 2012-07-26 |
| FR2948381B1 (fr) | 2013-07-12 |
| FR2948381A1 (fr) | 2011-01-28 |
| CA2767929A1 (fr) | 2011-01-27 |
| JP5758891B2 (ja) | 2015-08-05 |
| JP2013500003A (ja) | 2013-01-07 |
| CN102471761A (zh) | 2012-05-23 |
| EP2456854A1 (fr) | 2012-05-30 |
| NZ597728A (en) | 2013-11-29 |
| MX2012001004A (es) | 2012-05-29 |
| ES2650664T3 (es) | 2018-01-19 |
| WO2011009706A1 (fr) | 2011-01-27 |
| US9243228B2 (en) | 2016-01-26 |
| EP2456854B1 (fr) | 2017-08-30 |
| IL217352A0 (en) | 2012-02-29 |
| IL217352A (en) | 2016-03-31 |
| AU2010275678A1 (en) | 2012-02-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4056685A1 (en) | Primary breast epithelial cell culture medium, culture method, and use thereof | |
| US11530385B2 (en) | Hormone responsive tissue culture system and uses thereof | |
| JP7434359B2 (ja) | 胃がん及び胆嚢・胆管がん初代細胞を培養する方法及び補助試薬 | |
| WO2021184408A1 (zh) | 胃癌原代细胞的培养基及培养方法 | |
| EP3239294A1 (en) | Primitive gut endoderm cells and method for producing same | |
| AU2010275678B2 (en) | Method for obtaining myofibroblasts | |
| Liu et al. | Cell-to-cell contact induces human adipose tissue-derived stromal cells to differentiate into urothelium-like cells in vitro | |
| Warschkau et al. | From 3D to 2D: harmonization of protocols for two-dimensional cultures on cell culture inserts of intestinal organoids from various species | |
| US20220267735A1 (en) | Method for culturing primary cells from solid tumor of lung cancer and primary tumor cells from pleural effusion of lung cancer and auxiliary reagents | |
| WO2022227110A1 (zh) | 口腔癌原代细胞的培养基及培养方法 | |
| Hosseini et al. | A mechanical non-enzymatic method for isolation of mouse embryonic fibroblasts | |
| CN114891735A (zh) | 一种乳腺上皮类器官模型构建方法 | |
| Pettinato et al. | Development of a scalable three-dimensional culture of human induced pluripotent stem cells-derived liver organoids | |
| Rubio et al. | Generation of mosaic mammary organoids by differential trypsinization | |
| Caduc et al. | Stem Cell Niche: iPSC-Based Assembloids for Modeling Human Hematopoiesis | |
| Pettinato | Generation of hepatocyte organoids from human iPS cells | |
| Holthaus et al. | Establishing and Maintaining 3D Organoid Cultures From Human Fallopian Tube Epithelium | |
| Wu | Growth of Human Lung | |
| CN118685360B (zh) | 一种人源去分化脂肪肉瘤细胞系和应用 | |
| Grunberg et al. | Fat’s all, folks: culturing and manipulating peri-prostatic adipocytes to probe impacts on prostate cancer biology | |
| RU2631005C1 (ru) | Способ культивирования клеток слюнной железы человека | |
| Roshandel et al. | Accelerated Limbal Epithelial Differentiation of Human Induced Pluripotent Stem Cells Using a Defined Keratinocyte Serum-Free Medium | |
| CN105219732A (zh) | 一种永生化人肝癌血管内皮细胞系及其制备方法和应用 | |
| Sigurdardottir et al. | Application of 3D culture assays to study breast morphogenesis, epithelial plasticity, and cellular interactions in an epithelial progenitor cell line | |
| Kuhna | Developing Ovarian Organoids to Study Ovary Function: Organoid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |